Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy

Dall’Oglio, Marcos F.; Sousa-Canavez, Juliana M.; Tanno, Fabio Y; Tiseo, Bruno Camargo; Crippa, Alexandre; Reis, Sabrina T.; Leite, Kátia R. M.; Srougi, Miguel

doi:10.1590/s1677-55382011000200004

Cited by 5 publications

(2 citation statements)

References 25 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This balances out the lower prognostic risk of the patients in this study. Durable SD lasting 9–10 months was reported by Dall'Oglio et al, for patients with metastatic RCC who were treated with DC vaccination in combination with nephrectomy and sunitinib . Median PFS or OS for sunitinib or pazopanib used as the first‐line treatment for patients with advanced RCC has been reported to be 9.5, 29.1 and 9.2 m, 22.9 m, respectively .…”

Section: Discussionmentioning

confidence: 80%

Vaccination of Urological Cancer Patients With WT1 Peptide‐Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses

2018

View full text Add to dashboard Cite

The prognosis of metastatic or relapsed renal cell carcinoma (RCC) or bladder cancer (BC) remains poor despite the introduction of immune checkpoint blockade agents. We aimed to investigate the safety and the feasibility of a vaccination with WT1 peptide-loaded dendritic cells (DCs) and OK-432 adjuvant combined with molecular targeted therapy or conventional chemotherapy. Five eligible patients with metastatic or relapsed RCC and five eligible patients with BC were enrolled. No severe adverse events related to a vaccination were observed. Seven patients with RCC or non-muscle invasive BC had durable stable disease and three other patients had disease progression after DC vaccination. DC vaccination augmented WT1 specific immunity and the reduction of regulatory T cells which might be related to clinical outcome. These results indicate that DC-based immunotherapy combined with a molecular targeted therapy or a conventional chemotherapy is safe and feasible for patients in advanced stage of RCC or BC.

show abstract

Section: Discussionmentioning

confidence: 80%

Vaccination of Urological Cancer Patients With WT1 Peptide‐Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses

2018

View full text Add to dashboard Cite

show abstract

“…These two patients displayed disease stabilization after sunitinib treatment and regression of metastatic lesions after nephrectomy and DC vaccine, suggesting that sunitinib could synergize with DC vaccine (95). In an open-label phase II trial, 21 metastatic renal cancer patients received sunitinib and a DC-based vaccine (AGS-003).…”

Section: Impact Of Strategy Combining Anti-angiogenic Therapy With Immentioning

confidence: 99%

Control of the Immune Response by Pro-Angiogenic Factors

et al. 2014

View full text Add to dashboard Cite

The progressive conversion of normal cells into cancer cells is characterized by the acquisition of eight hallmarks. Among these criteria, the capability of the cancer cell to avoid the immune destruction has been noted. Thus, tumors develop mechanisms to become invisible to the immune system, such as the induction of immunosuppressive cells, which are able to inhibit the development of an efficient immune response. Molecules produced in the tumor microenvironment are involved in the occurrence of an immunosuppressive microenvironment. Recently, it has been shown that vascular endothelial growth factor A (VEGF-A) exhibits immunosuppressive properties in addition to its pro-angiogenic activities. VEGF-A can induce the accumulation of immature dendritic cells, myeloid-derived suppressor cells, regulatory T cells, and inhibit the migration of T lymphocytes to the tumor. Other pro-angiogenic factors such as placental growth factor (PlGF) could also participate in tumor-induced immunosuppression, but only few works have been performed on this point. Here, we review the impact of pro-angiogenic factors (especially VEGF-A) on immune cells. Anti-angiogenic molecules, which target VEGF-A/VEGFR axis, have been developed in the last decades and are commonly used to treat cancer patients. These drugs have anti-angiogenic properties but can also counteract the tumor-induced immunosuppression. Based on these immunomodulatory properties, anti-angiogenic molecules could be efficiently associated with immunotherapeutic strategies in preclinical models. These combinations are currently under investigation in cancer patients.

show abstract